The Role of PARP2 in Prostate Cancer
Abstract
Androgen receptor (AR) is a key driver of prostate cancer (PCa) growth and progression. Understanding the factors influencing AR-mediated gene expression provides new opportunities for therapeutic intervention. The goal of our research is to develop novel therapeutic strategies for advanced PCa. Poly(ADP-ribose) Polymerase (PARP) is a family of enzymes, which post-translationally modify a range of proteins and regulate many different cellular processes. PARP1 and PARP2 are two well characterized PARP members, whose catalytic activity is induced by DNA-strand breaks and responsible for multiple DNA damage repair pathways. PARP inhibitors are new therapeutic agents that show synthetic lethality against many types of cancer with homologous recombination DNA-repair deficiency. Here, we found that beyond DNA damage repair function, PARP2, but not PARP1, is a critical component in AR transcriptional machinery through interacting with the pioneer factor FOXA1 and facilitating AR recruitment to genome wide prostate-specific enhancer regions. Selective targeting of PARP2 by genetic or pharmacological means blocks interaction between PARP2 and FOXA1, which in turn attenuates AR-mediated gene expression and inhibits PCa growth. Next-generation anti-androgens (such as enzalutamide and abiraterone) act through inhibiting androgen synthesis or blocking ligand binding. Selective targeting of PARP2, however, may provide an alternative therapeutic approach for AR inhibition by disruption of FOXA1 function, which may be beneficial to patients when current anti-androgens fail.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2021
- Accession Number
- AD1170624
Entities
People
- Li Jia
Organizations
- Brigham and Women's Hospital